Broad respiratory multiplex panels appear to be a strong fit for Europe’s hospital and public health needs. However, the commercial path is less straightforward. Demand exists, but because much of it comes from narrow or seasonal use cases, suppliers can be left carrying the cost of the panels without getting the repeat volume needed to scale them widely.
Hospital budgets limit routine respiratory PCR panel adoption
Broad multiplex panels detect multiple pathogens simultaneously from a single sample. However, adoption is often limited as many hospitals must pay for these tests from existing inpatient budgets. In many European inpatient settings, laboratories do not receive separate reimbursement for adopting a new respiratory panel. This creates pressure to justify why hospitals should routinely use the panel.
Broad multiplex panels can provide faster and more comprehensive results than sequential testing. This helps clinicians to make quicker decisions on patient isolation and treatment. They can also improve patient management, particularly during peak respiratory seasons. However, they do not automatically translate into visible or immediate cost savings for hospitals.
Respiratory PCR panels show value, but savings remain hard to prove
Faster pathogen detection offers clinical value, including better prescribing and infection control. But it is harder to turn benefits such as reduced length of stay or improved bed management into actual cost savings. For example, if a patient is discharged early, the bed is usually filled immediately by another patient, so the hospital’s staffing and infrastructure costs stay the same. As a result, while operations run more smoothly, the actual financial impact becomes difficult to measure.
Recent research shows this challenge. A 2023 European community-acquired pneumonia (CAP) study found that PCR respiratory panels can reduce average diagnostic costs. However, a 2024 Spanish trial showed that faster pathogen identification did not significantly reduce antibiotic use. This shows that even with some financial and clinical advantages, broad multiplex panels do not guarantee hospital-wide savings.
Hospitals surely recognize the clinical value of broad multiplex panels. But suppliers must still prove that these tests influence treatment decisions often enough to justify regular purchasing. Consequently, demand is likely to concentrate where rapid results have an immediate effect on care.
High-acuity cases offer the strongest repeat demand
The most defensible repeat demand for broad multiplex panels is likely to come from high-acuity clinical cases such as ICU cases, severe pneumonia, immunocompromised patients, etc. Rapid pathogen identification can directly influence immediate treatment decisions in these use cases. Physicians may also need to adjust, stop, or change antibiotics quickly, decide on isolation measures, or manage outbreaks. In these settings, clinicians mostly use broad multiplex panels as decision-support tools rather than general screening tests.
Hospitals are more likely to continue ordering a higher-cost panel when there are clear guidelines on when to use it, and clinicians know how to act on the results. Without these protocols, use may become inconsistent, labs will likely face pressure to limit testing, and implementation support will become part of the sale. Suppliers that help hospitals set ordering rules and result follow-up may have a better chance of keeping panel use from being cut back after initial adoption.
CAP studies also highlight how routine use is less compelling for hospitals. Across European guidelines and HTA sources, broad multiplex panels appear better supported for severe or high-risk hospital cases than for routine use for all CAP patients. But this significantly limits the target patient pool for the panels. Research on repeated respiratory panel use also suggests that repeated testing over short intervals often provides limited additional diagnostic value. If hospitals restrict testing to high-risk individuals and limit repeat orders, growing consistent cartridge sales will be difficult for suppliers. Volume may still temporarily spike during winter surges, outbreaks, or shifts in hospital protocols.
Seasonal respiratory PCR demand still limits year-round volume
Outbreaks and seasonal surges in respiratory infections can create periods of strong demand for broad multiplex panels. During flu, RSV, or COVID-19 peaks, these tests can help with triage, infection control, antiviral selection, and outbreak investigations. However, this demand is concentrated during specific parts of the year. While it can increase reagent or cartridge use during peak periods, it does not necessarily translate into steady year-round hospital use.
This makes hospital commercialization more complex than a simple sale based on clinical evidence. Panel makers may need to convince ICU teams, infection-control teams, antimicrobial stewardship leads, and lab managers separately, as each group focuses on a different use case. As a result, adoption will likely lead to steady use in niche, high-acuity cases rather than high-volume, routine use across all respiratory admissions.
Related reading:
Broad Respiratory Panels Find Clinical Value, but Not Routine Volume in the USA
Public health surveillance brings steadier but narrower PCR demand
Public health surveillance programs can offer a more planned source of respiratory testing demand than routine hospital diagnostics, especially through seasonal programs. Across Europe, ECDC and WHO surveillance frameworks now incorporate influenza, RSV, and SARS-CoV-2 monitoring within broader respiratory virus tracking programs. For suppliers, this can create reliable, repeat seasonal orders. It can also build stronger relationships with public health institutes, reference laboratories, and high-throughput testing networks.
This demand is still not guaranteed or evenly spread throughout the year, as it can depend on seasonality, public budgets, outbreaks, and changing surveillance priorities. However, it is much more predictable than hospital sales because public health buyers are not waiting for rapid bedside results. Instead, they need consistent, comparable, and practical testing across large sample volumes.
This difference in buying behavior also changes the type of products panel makers can sell. Surveillance programs typically focus on specific viruses such as influenza, RSV, and SARS-CoV-2. A very broad panel that detects extra pathogens may not add enough value to justify its use. Public health buyers also do not make purchasing decisions solely based on cost. They consider whether the panel fits their specific purpose. This includes regular seasonal monitoring, standardized results, high-volume processing, and responsible use of public money.
Tenders favor focused respiratory tests over broad panels
Tender-based procurement systems also reinforce this pattern. Buyers focus on cost efficiency, standardization, and high-volume testing capacity. As a result, suppliers are more likely to win contracts by offering reliable, focused tests that generate steady cartridge sales. Broad multiplex panels may play a stronger role in outbreak and special investigations or reference lab work.
Public health surveillance offers a steady but limited revenue stream for broad multiplex panel makers. While it can support repeat seasonal orders, it is unlikely to support a large premium broad multiplex panel strategy on its own.
EOS Implic-Action: Fragmented demand favors modular respiratory PCR strategies
Europe may create demand for broad multiplex respiratory panels, but that demand is likely to remain split across too many narrow use cases. Hospitals, ICUs, public health institutes, and seasonal respiratory programs have different reasons for testing. They also have different budgets and margins for paying for broader pathogen coverage. This could make it difficult for one premium broad panel to scale easily.
Due to this market fragmentation, suppliers may need separate clinical evidence and commercial cases for each setting. This makes winning a new hospital or laboratory more expensive. As a result, suppliers need to secure repeat purchases from the same customer. They cannot rely only on occasional orders for broad panels.
Modular testing menus can support this approach. They allow suppliers to offer targeted seasonal panels, wider panels for severe hospital cases, and outbreak-related panels to the same customer year-round. In EU markets, IVDR can add cost because suppliers may need to keep proving and updating several panel formats. If one format brings only small or occasional orders, it may become harder to justify keeping it on the market.
This environment is more likely to favor focused flu/RSV/SARS-CoV-2 assays. These assays support routine seasonal testing and surveillance programs better than broader panels that fit selected hospital and outbreak use. Suppliers with both focused and broader panels may be less dependent on occasional broad-panel orders and have more opportunities to keep the same customer buying across the year. This advantage is stronger when the supplier already has an instrument in the hospital or lab. Adding another panel is easier than convincing the buyer to bring in a new system.
Explore more analysis on EOS Implicium
Smaller, specialized suppliers can still find opportunities in public health or seasonal testing, especially by offering affordable, high-volume tests. However, this route does not automatically create a strong business. Public buyers may push on price, orders may be seasonal, and fixed virus lists may limit what they can sell. For smaller players, market entry will only be the first hurdle. They will also need enough repeat orders beyond the first contract or first lab placement.
In Europe, respiratory multiplex testing is likely to grow through targeted repeat-use applications rather than through one large product used everywhere. Suppliers that can match panel breadth to buyer needs and generate repeat orders across several narrow uses are more likely to make the European opportunity worth the cost.